I'm an early investor in FemPulse, founded by a urogynecologist to commercialize her patented bioelectronic female health platform. The first big application of the vaginally-inserted and removable FemPulse Ring is the 1 in 6 women worldwide with overactive bladder. There is a huge market need between ineffective medication and effective but inherently limited surgically implanted neuromodulation. FemPulse’s “internal wearable” non-implanted neuromodulation device should be approved in Europe in 2025. Now FDA has given FemPulse an early Christmas present by approving the U.S. pivotal study.
that is very good news!
Congrats
Félicitations Robert!
Thanks for sharing Robert Taub ! Congratulations !
Congratulations Robert!
Congratulations Robert!
sales and Clinical Representative
1dThis is wonderful! Thank you for investing in womens health and the much needed advancements in current treatment options. Keep pushing the medical field forward!